Abstract 70P
Background
Methotrexate is an important component of acute lymphoblastic leukemia (ALL) protocols and methotrexate toxicity can at times lead to fatal complications which are unpredictable. Understanding gene polymorphisms is important as antidote to toxicity is not widely available and febrile neutropenia is deadly for patients with remote access to health care system in developing counties. This study was undertaken to analyse the toxicities in patients receiving high dose methotrexate and their association with methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms.
Methods
MTHFR gene polymorphisms (A1298C & C677T) were analysed using real time polymerase chain reaction on peripheral blood of patients with acute lymphoblastic leukemia receiving high dose methotrexate (HDMTx, methotrexate > 500 mg per square meter) and methotrexate toxicities were analysed. Statistical analysis was done by chi-square test.
Results
A total of 51patients received high dose methotrexate therapy, out of which 27 patients had MTHFR gene polymorphisms and 24 patients had no polymorphisms. Grade3 and 4 toxicities were seen in 16 of 51 patients (31%) of which 14patients (87.5%) had gene polymorphisms and 2 patients had no polymorphisms. All patients with toxicities having polymorphisms were heterozygous, A1298C in 9patients (64%), C677T in 5 patients (35%). Homozygous polymorphisms were not seen in any patient. A significant association was seen between MTHFR gene polymorphisms and methotrexate toxicity (p-value 0.000828) compared to those without polymorphisms.
Conclusions
Testing for MTHFR gene polymorphisms is important before starting high dose methotrexate as these patients need to be monitored carefully and dose adjustments need to be done to prevent morbidity and unpredictable mortality.
Editorial acknowledgement
Clinical trial identification
NA
Legal entity responsible for the study
NIMS, Hyderabad.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract